<DOC>
	<DOC>NCT01081704</DOC>
	<brief_summary>A study of the pharmacokinetics of ustekinumab in Chinese male subjects.</brief_summary>
	<brief_title>A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects</brief_title>
	<detailed_description>This is a randomized (study medication assigned by chance), open-label (both the physician and subject know the assigned study medication) study to assess the safety, tolerability, immune response, pharmacokinetics (what the body does to the drug), of ustekinumab (Stelara). The study population will consist of 24 healthy male participants in China. Participants will receive a single dose of either 45mg or 90 mg ustekinumab. Participants will be in the study for up to 16 weeks. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. A single dose of 45 mg or 90 mg ustekinumab.</detailed_description>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have no clinically relevant abnormalities Non smoker Have or had a history of clinically significant, severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Have any underlying physical or psychological medical condition Be unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Chinese male</keyword>
	<keyword>Stelara</keyword>
</DOC>